IRIDEX Corporation Stock News

MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal

IRIDEX Corporation is a leading provider of laser-based retinal treatments and is respected in the ophthalmic industry. IRIX stock has experienced a significant decline in value, but the primary reaso

MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advi

IRIDEX Corporation (NASDAQ:IRIX ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Philip Taylor - Gilmartin Group David Bruce - President, CEO & Director Fuad Ahmad -

Iridex (IRIX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.

The Zacks Laser Systems and Components industry participants like IPG Photonics (IPGP) and IRIDEX (IRIX) gain from solid demand for emerging applications like autonomous driving, IoT, 5G and healthcar

Iridex (IRIX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.15 per share a year ago.

MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal

IRIDEX Corporation (NASDAQ:IRIX ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fua

Iridex (IRIX) delivered earnings and revenue surprises of 36.36% and 0.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal

IRIDEX Corporation (NASDAQ:IRIX ) Q3 2022 Results Conference Call November 10, 2022 5:00 PM ET Company Participants David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer C

Iridex (IRIX) delivered earnings and revenue surprises of 26.67% and 5.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

The stock price of IRIDEX (IRIX) fell by 8.58% in the previous trading session. This is why.

MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal